Welcome to CDC stacks | Medication use and the risk of motor vehicle collision in West Virginia drivers 65 years of age and older: a case-crossover study - 41020 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Medication use and the risk of motor vehicle collision in West Virginia drivers 65 years of age and older: a case-crossover study
Filetype[PDF-963.69 KB]


Details:
  • Pubmed ID:
    26979111
  • Pubmed Central ID:
    PMC4791935
  • Description:
    Background

    The current generation of older adults reports a higher lifetime prevalence of prescription, over-the-counter, and recreational drug use. The purpose of this analysis is to characterize the drug usage and determine the risk of motor vehicle collision associated with individual medications in a population of drivers ≥65 years.

    Methods

    A case-crossover study was conducted at West Virginia University Healthcare’s facilities using data obtained from the electronic health records (n = 611) of drivers ≥65 years admitted for medical treatment following a motor vehicle collision which occurred between Jan. 1, 2009 and June 30, 2014. Patients’ medication usage 14 days before collision were matched and compared to their medication usage during four control periods prior to collision. Odds ratios were then calculated for the most prevalent individual medications and pharmaceutical sub-classes using conditional logistic regression.

    Results

    Analgesic, cardiovascular and gastrointestinal medicines were common. Few drivers tested positive for either licit or illicit drugs. Of those testing positive for drugs, benzodiazepines and opiates were prevalent. Drivers consuming Tramadol (adjusted OR 11.41; 95 % CI 1.27, 102.15) were at a significantly increased risk of motor vehicle collision.

    Conclusions

    Older adult drivers who have a prescription for this medication may need to be aware of the potential risk. Further research is necessary in a larger, more nationally representative population.

  • Document Type:
  • Collection(s):
  • Funding:
    R01 AG050581/AG/NIA NIH HHS/United States
    R01 HD074594/HD/NICHD NIH HHS/United States
    R01HD074594/HD/NICHD NIH HHS/United States
    R21 HD085122/HD/NICHD NIH HHS/United States
    R21CE001820/CE/NCIPC CDC HHS/United States
    R49CE002109/CE/NCIPC CDC HHS/United States
    U54 GM104942/GM/NIGMS NIH HHS/United States
    U54GM104942/GM/NIGMS NIH HHS/United States
No Related Documents.
You May Also Like: